Andrews David M, Swarbrick Martin E, Merritt Andrew T
Oncology iMed Chemistry, AstraZeneca, Mereside, Alderley Park, Macclesfield, SK10 4TF, UK.
Cancer Research Technology, Jonas Webb Building, Babraham Research Campus, Cambridge, CB22 3AT, UK.
Drug Discov Today. 2014 Apr;19(4):496-501. doi: 10.1016/j.drudis.2014.01.009. Epub 2014 Jan 28.
In response to the dual challenges of increasingly risky target portfolios and realignment of traditional pharmaceutical company resources away from early-phase research and development (R&D), research groups have sought to engage across the industrial and not-for-profit divide, resulting in the emergence of many different collaborative models. Here, we describe two successful collaborations based upon shared commitment and risk. The risks and complexities of external collaboration can be mitigated by appropriate agreements and tools, but we found that it remains essential that the collaborating scientists adopt a collaborative mindset and embrace the diverse ways of working of partner organizations.
面对目标投资组合风险日益增加以及传统制药公司将资源从早期研发重新分配的双重挑战，研究团队寻求跨越产业界与非营利部门的界限进行合作，从而催生了许多不同的合作模式。在此，我们描述了基于共同承诺和风险的两项成功合作。外部合作的风险和复杂性可通过适当的协议和工具来缓解，但我们发现，合作科学家秉持合作心态并接受合作伙伴组织的多样化工作方式仍然至关重要。
